Skip to main content
. Author manuscript; available in PMC: 2019 Oct 9.
Published in final edited form as: J Am Coll Cardiol. 2018 Oct 9;72(15):1856–1869. doi: 10.1016/j.jacc.2018.07.071

Figure 2: Summary of Reductions in Major Adverse Cardiac Events in recent GLP-1 RA trials.

Figure 2:

CV, cardiovascular; GLP-1 RA, glucagon-like peptide receptor agonist; MACE, major adverse cardiac events; MI, myocardial infarction. Liraglutide and semaglutide significantly reduced MACE-3 in LEADER and SUSTAIN-6, respectively. Liraglutide significantly reduced CV death, heart-failure hospitalization, and all-cause mortality. Semaglutide significantly reduced non-fatal stroke.